STE20 like kinaseGenealiases: LOSK · STK2 · bA16H23.1 · se20-9
Q-omics provides the consensus-scored SLK profile across patient tissues and cancer cell-line models. SLK expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLK is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, SLK protein abundance shows 27,713 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, THCA, and HNSC as cancer lineages where SLK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLK survival associations across molecular data types. SLK RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLK RNA expression–survival associations across cancer types. High SLK expression shows unfavorable associations in ACC and PAAD, but favorable associations in KIRC, UCS, SCLC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLK RNA expression.
This table summarizes SLK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLK shows lower tumor expression in THCA, UCEC, KICH and BRCA and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher SLK RNA expression in normal versus tumor tissue (log2 FC = −0.625, t-test p < 0.001).
This table shows molecular features associated with SLK in patient tissues and cancer cell lines. In patient samples, SLK shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
